The new modulating drugs for the treatment of the Cystic Fibrosis’ underlying defect improve but do not resolve inflammation and chronic airways’ infection. In previous FFC projects, this research group has shown that L-Miglustat can act as anti-inflammatory and that it also exhibits antibacterial effect. Now the group intends to investigate the latter on the most common bacteria in CF patients. New more effective L-Miglustat’s derivative will be synthesized (University of Naples Federico II), and they will be studied in vitro to verify cytotoxicity in CF bronchial cells (University of Ferrara); moreover, they will be evaluated for their antimicrobial and antibiofilm activity, either alone or administered with other antibiotics. Eventually the most effective derivative will be evaluated in mouse models of acute and chronic infection and validated in FC mice (AOUI of Verona). The goal is to move from an already known molecule to a new compound with both anti-inflammatory and antibacterial effects against CF respiratory infections, with the perspective of a quick transition to clinical trials.